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Abstract
The tumor-node-metastasis (TNM) staging system has been the anchor of can-
cer diagnosis, treatment, and prognosis for many years. For meaningful clinical
use, an orderly, progressive condensation of the T and N categories into an over-
all staging system needs to be defined, usually with respect to a time-to-event
outcome. This can be considered as a cutpoint selection problem for a censored
response partitioned with respect to two ordered categorical covariates and their
interaction. The aim is to select the best grouping of the TN categories. A novel
bootstrap cutpoint/model selection method is proposed for this task by maximiz-
ing bootstrap estimates of the chosen statistical criteria. The criteria are based on
prognostic ability including a landmark measure of the explained variation, the
area under the ROC curve, and a concordance probability generalized from Har-
rell’s c-index. We illustrate the utility of our method by applying it to the staging
of colorectal cancer.
A Systematic Selection Method for
the Development of Cancer Staging Systems
Yunzhi Lin1, Richard Chappell1,2, and Mithat Go¨nen3
1Department of Statistics, University of Wisconsin - Madison, Madison, WI 53706, U.S.A.
2Department of Biostatistics & Medical Informatics, University of Wisconsin - Madison,
Madison, WI 53706, U.S.A.
3Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center,
1275 York Avenue, New York, NY 10065, U.S.A.
Abstract
The tumor-node-metastasis (TNM) staging system has been the anchor of cancer
diagnosis, treatment, and prognosis for many years. For meaningful clinical use, an
orderly, progressive condensation of the T and N categories into an overall staging
system needs to be defined, usually with respect to a time-to-event outcome. This can
be considered as a cutpoint selection problem for a censored response partitioned with
respect to two ordered categorical covariates and their interaction. The aim is to select
the best grouping of the TN categories. A novel bootstrap cutpoint/model selection
method is proposed for this task by maximizing bootstrap estimates of the chosen
statistical criteria. The criteria are based on prognostic ability including a landmark
measure of the explained variation, the area under the ROC curve, and a concordance
probability generalized from Harrell’s c-index. We illustrate the utility of our method
by applying it to the staging of colorectal cancer.
Keywords: Cancer staging; TNM System; Bootstrap; Model selection; Sur-
vival Analysis.
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1 Introduction
The development of accurate prognostic classification schemes is of great interest and concern
in many areas of clinical research. In oncology, much effort has been made to define a
cancer classification scheme that can facilitate diagnosis and prognosis, provide a basis for
making treatment or other clinical decisions, and identify homogeneous groups of patients
for clinical trials. Among various classification schemes, the tumor-node-metastasis (TNM)
staging system is widely used because of its simplicity and prognostic ability.
The basis of TNM staging is the anatomic extent of disease. It has three components:
T for primary tumor, N for lymph nodes, and M for distant metastasis. TNM staging is
periodically updated. Using its 6th edition, in the case of colorectal cancer which we will
use as an example in this paper, there are 4 categories of T, 3 of N, and 2 of M [1]. Details
of the categories are provided in Table 1. These TNM categories jointly define 24 distinct
groups, which are unwieldy for meaningful clinical use [2]. Therefore, the American Joint
Committee on Cancer (AJCC) and International Union against Cancer (UICC) defined an
orderly, progressive grouping of the TNM categories which reduces the system to fewer stages
(4 main stages and 7 sub stages under the 6th edition [1], see Figure 1). Alternative grouping
schemes have also been proposed by other authors.
Table 1: The TNM staging system for colorectal cancer
T : Primary Tumor
T1 Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades into pericolorectal tissues
T4 Tumor directly invades or is adherent to other organs
N : Lymph Nodes
N0 No regional lymph node metastasis
N1 Metastasis in 1-3 regional lymph nodes
N2 Metastasis in 4 or more regional lymph nodes
M : Distant Metastasis
M0 No distant metastasis
M1 Distant metastasis
The value and usefulness of these TNM staging systems are, however, very much debated
[3]. The main concerns are that the AJCC system is defined without systematic empirical
investigation (by systematic, we mean the extensive division of the table in Figure 1 into
all possible staging systems) and that it has too many (6) stages [2]. There is also a lack
of commonly accepted statistical methods for developing staging systems. These critiques
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Figure 1: Schematic showing the AJCC 6th edition staging system for colorectal cancer.
apply to staging all types of cancers.
Here and below, M1 patients will be omitted and relegated, as they usually are, to
separate consideration. The reasons for this are two-fold: (1) M1 cancers are considered
systemic diseases, as opposed to M0, which is considered localized; and (2) M1 has historically
been the strong indicator of poor prognosis for almost all cancers. Currently, most studies on
cancer staging systems are focused on evaluating and comparing existing proposals of TNM
groupings [4, 5, 6]. However, we note that the AJCC system, as well as other proposed
systems based on TNM, represent only a few of the numerous combinations of the T and
N categories. We believe a thorough evaluation of all possible T and N combinations with
respect to a possibly censored time-to-event outcome would be a more sensible way to develop
good staging systems. Our goal is to answer the question: does the AJCC staging scheme
outperform other possible T and N combinations in prognosis? If not, what is the best
system out of all possible T and N combinations?
Searching for the best TNM grouping posed a challenging statistical problem. In this
paper, a bootstrap model/cutpoint selection method is proposed for this task based on the
following considerations. First, not all TNM combinations are eligible staging systems. As
both categories are ordinal, only those combinations are eligible which are ordered in T given
N and vice versa. A search algorithm that satisfies this partial ordering rule is proposed
for generating all eligible staging systems. Second, the best staging systems can be simply
defined as the ones that optimize the selection criterion chosen. Ideally, an external validation
with a new population is desirable before determining the best system. In the absence
of independently collected data, bootstrapping could be used as an alternative to provide
replicate data sets for validating the selection [7]. Hence a bootstrap resampling strategy is
proposed to estimate the optimal staging system, and to provide inference procedures (e.g.
confidence intervals).
Selection criteria need to be identified that quantify the prognostic ability of candidate
staging systems. A common approach for model development based on censored survival
data is through the use of Cox proportional hazards model. Whereas the partial likelihood
2
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function as a statistical criterion is informative for looking at magnitude of effect, in certain
clinical situations it might not be the most desirable option. It might be difficult to interpret
for a non-statistician. Furthermore, since our problem is centered on evaluating prognostic
classification schemes, which are inherently fully categorical and hence model-free, measures
that check goodness-of-fit or that address model selection are less suitable for the task at
hand. In view of these considerations, we elect to use measures that directly assess the
prognostic ability of the staging systems. Several measures and ad hoc methods have been
proposed for assessing prognostic ability; detailed reviews of these measures have been given
by Schemper and Stare [8] and by Graf et al. [9], among others. In this paper, we elect to use
the three criteria proposed by Begg et al. [6] and adapt them for comparison with our search
algorithm: the explained variation for a specified ”landmark” time, the area under the ROC
curve for a landmark, and a concordance probability generalized from Harrells c-index.
The structure of the paper is as follows. In Section 2 we describe the motivating data
example of colorectal cancer patients. The bootstrap selection method is described in Section
3 and the criteria for finding the optimal staging system are explained in Section 4. The
method is then illustrated on the colorectal cancer example in Section 5. Discussions and
conclusions are given in Section 6.
2 Motivating Example: Colorectal Cancer
We based our analysis on the de-identified database of 1,326 patients with non-metastatic
colon cancer treated at Memorial Sloan-Kettering Cancer Center between January 1, 1990
and December 27, 2000 [10]. All patients are diagnosed with AJCC stage 1 to 3c disease (6th
edition). The primary outcome used in the analysis is cancer-specific survival (only deaths
attributable to recurrent cancer were counted as events). Of the 1,326 patients, 379 died by
end of follow-up and the median survival was 115 months. Median follow-up time was 61.4
months. Table 2 presents the sample size, hazard ratio, and 10-year survival for each cell in
the T×N table. With a couple of exceptions, apparently due to small sample sizes, there is
a strong upward trend in risk with increasing T and N involvement. However, we observe a
relatively poor separation of the Kaplan-Meier survival curves under the AJCC 6th edition
staging system (Figure 2).
3
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Table 2: Estimated cancer-specific 10-year survivals/hazard ratios by TNM classifications
(sample size).
T1 T2 T3 T4
N0 0.87/1.00 (213) 0.73/2.44 (209) 0.33/5.63 (468) 0.50/4.99 (53)
N1 0.83/0.93 (14) 0.57/2.54 (34) 0.36/5.56 (197) 0.58/6.00 (27)
N2 0.50/4.37 (3) 1.00/0.00 (5) 0.33/8.00 (81) 0.43/10.27 (22)
Figure 2: Cancer-survival of colorectal cancer patients by the 6th edition AJCC staging
system: (A) three main stages; (B) including sub stages.
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3 Method
To identify the best staging system, we propose a search algorithm that scans through all
eligible possibilities. In general, suppose the T descriptor has p categories, the N descrip-
tor has q categories, and a k-stage system is desirable. The problem can be described by
borrowing the framework of an outcome-oriented cutpoint selection problem for a censored
response partitioned with respect to two ordered categorical covariates and their interaction.
That is, we aim to estimate the best k−1 partition lines (cutpoints) that classify a partially
ordered p× q table into k ordinal groups.
4
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Calculating the number of all eligible partitions falls into the general mathematical prob-
lem of compositions of a grid graph [11], yet an analytical solution is not available for the
general case. Numerical solutions can be obtained through computerized enumeration for
small k, p, and q values, and they are given in Table 3 for small k’s with p = 4 and q = 3,
relevant to our colorectal cancer example.
Table 3: Number of eligible staging systems given k.
number of stage k 2 3 4 5 6
number of eligible systems 33 388 2,362 8,671 20,707
A value nmin is pre-specified for the minimum size of a stage, for example, nmin equals
5% of the sample size. Any system violating the nmin criterion will be dropped, and the
remaining are the candidate systems. Let S denote the set of candidate systems, and let
Ts denote the selection criterion value (see technical discussions in Section 4) for candidate
system s ∈ S. The maximally selected criterion is
Tmax = maxsTs. (1)
The maximally selected TN combination s∗ is defined to be the one for which the maximum
is attained, that is, for which the value of statistical criterion Ts∗ equals Tmax given k.
Our task differs from the usual cutpoint estimation problem which utilizes the maximally
selected statistics. Under the maximally selected tests, the null hypothesis of interest is
the independence between the covariate (to be dichotomized) and the response, and the
estimation of a cutpoint comes after the rejection of the null hypothesis. This null hypothesis
is irrelevant in our case as the prognostic ability of the T and N categories is well established
and assumed to hold. Our inquiry takes one step further to ask, is the maximally selected
TN combination s∗ truly the optimal staging system for the population?
A bootstrap model selection strategy is therefore applied to estimate the optimal staging
system. B bootstrap samples of size n (where n is the original sample size) are drawn with
replacement from the original data. Denoting the bootstrap replication of Tˆs by Tˆ
b
s , the
bootstrap estimated criterion for candidate system s is given by
T˜s =
1
B
B∑
b=1
Tˆ bs . (2)
The bootstrap estimate of the best staging system s˜∗ is defined as the system that maximizes
T˜s.
There are two reasons that lead us to choose the bootstrap procedure:
5
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1. The bootstrap method provides inference procedures (e.g. confidence intervals) for
not only the optimal selected but all candidate systems, which enables us to examine
the relative performance of any staging systems of interest and allows flexibility in
the decision making process for clinical researchers and practitioners. In the analysis
in Section 5, the standard bootstrap variance estimate was employed to construct
the variance estimates of the measures for each candidate system, and the confidence
intervals are also produced by bootstrapping.
2. The bootstrap selection procedure can easily adopt any measure of prognostic ability.
In the next part of this section, three such measures will be introduced and their
performance will be compared through simulations in Section 6.
Note that a complete search through all eligible partitions for all bootstrap samples
is, however, thwarted by combinational explosion. To overcome this problem, we can first
compute the criterion for each eligible system using the complete data, and then only include
the top m systems, say m = 200, (and the currently used staging system proposed by AJCC)
as the “finalists” for the bootstrap selection procedure.
4 Criteria for Assessing Staging Systems
In this section, we discuss the three measures/criteria we choose for assessing the prognostic
power of candidate staging systems.
4.1 Landmark Measures
An appealing way to simplify the analysis of survival data is to use a “landmark” time-point,
such as 5-year or 10-year survival, and deal with only the censored binary outcome. This is
frequently used in medical investigations. Here we elect to use the two landmark measures
described by Begg et al. [6], the explained variation and the area under the ROC curve. Let
θi, i = 1, . . . , c, denote the probabilities of survival at the chosen landmark time or each of
the c categories in the staging system, and pi denote the prevalence of the stage categories.
Let µ =
∑
piθi represent the unconditional mean outcome, and νi be the variance of θi.
Then the estimated proportion of explained variation pˆi is given by
pˆi =
∑
pˆiθˆ
2
i − (
∑
pˆiθˆi)
2 −∑ pˆiνˆi
(
∑
pˆiθˆi)(1−
∑
pˆiθˆi)
, (3)
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and the area under the ROC curve Aˆ is estimated as
Aˆ =
c∑
i=1
pˆi(1− θˆi)
2µˆ(1− µˆ)
{
2
i−1∑
j=1
pˆj θˆj + pˆiθˆi
}
(4)
where {θˆi} are the Kaplan-Meier [12] estimates of the survival probabilities at the landmark
time, {pˆi} are the observed relative frequencies of the staging categories, and {νˆi} are the
variances of the observed values of {θˆi} obtained from the Greenwood formula.
Using landmark times are less efficient statistically than using the entire survival dis-
tribution but provides for easier communication of results. In fact certain landmark times
have become standards of reporting in various cancers such as 5 and 10 years in localized
colorectal cancer. We include these measures also because in some situations landmark sur-
vival analysis can be more desirable than using the full survival. These include comparisons
in which proportionality is obviously violated (e.g., when one stage is usually treated with
a therapy which has a substantial immediate failure rate and another stage’s failures tend
to occur later) or those in which a landmark analysis is preferred for scientific reasons. An
example of the latter might be a childhood cancer in which life extension is less relevant
than the cure rate, and so a landmark measure such as 5-year survival could be used to stage
these patients as a surrogate for cure.
4.2 Concordance Probability
Harrell et al. [13, 14] proposed the c-index as a way of estimating the concordance proba-
bility for survival data. It is defined as the probability that, for a randomly selected pair of
participants, the person who fails first has the worse prognosis as predicted by the model.
A limitation of Harrell’s c-index is that it only takes into account usable pairs of subjects,
at least one of whom has suffered the event. Begg et al. proposed an improved estimator
of concordance which is adapted to account for all pairs of observations, including those for
which the ordering of the survival times cannot be determined with certainty [6]. It requires
the estimation of the probability of concordance for each pair of subjects and thus is compu-
tationally intensive for large sample sizes, particularly when bootstrapping. It also assumes
that if the patient with the shorter censored value lives as long as the observed censored
survival time in the paired patient, the remaining conditional probability of concordance is
1/2. As a result there is likely to be a conservative bias in the concordance estimator in the
presence of high censoring rates [6].
Here we develop an estimator of the concordance probability under a classification scheme.
Similar to Begg’s approach, the new method utilizes the Kaplan-Meier estimates to evaluate
7
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the probabilities. Let K be the probability of concordance. For two patients randomly
selected with stage (class) and survival time denoted by (S1, T1) and (S2, T2),
K = P{(S1 > S2, T1 < T2) or (S1 < S2, T1 > T2)}. (5)
Here we assume the survival time is inherently continuous although there could be ties in
observed survival times. If S1 = S2, then the most common approach is to consider it
equivalent to S1 > S2 with probability 1/2 and to S1 < S2 with probability 1/2. Thus (5)
can be written as
K = 2P (S1 > S2, T1 < T2) + P (S1 = S2, T1 < T2). (6)
Letting S1 = j and S2 = i, 1 ≤ i < j ≤ k, the first part of (6) can be estimated as
Pˆ (S1 > S2, T1 < T2) = Pˆ (T1 < T2|S1 > S2)Pˆ (S1 < S2)
=
∑∑
j>i
Pˆ (T1 < T2|j, i)Pˆ (j, i)
=
∑∑
j>i
Pˆ (T1 < T2|j, i) NjNi
N(N − 1)
(7)
where Ni, Nj are the sample sizes of stages i and j, respectively, and N is the total sample
size.
Given i and j, and the last event time in all groups denoted by tmax, we have
P (T1 < T2) = P (T1 < T2, T1 ≤ tmax) + P (T1 < T2, T1 > tmax). (8)
When at least one event occurred,
P (T1 < T2, T1 ≤ tmax) =
∫ ∞
0
dt2
∫ t2
0
f1(t1)f2(t2)dt1
=
∑
t∈{tj}
[Sj(t
−)− Sj(t)]Si(t)
(9)
where Si and Sj can be estimated by the Kaplan-Meier survival estimators in stage i and j,
and {tj} are the observed event times in stage j.
In the case when both observations are censored,
P (T1 < T2, T1 > tmax) = S1(tmax)S2(tmax)P (T1 < T2|T1, T2 > tmax). (10)
The conditional probability P (T1 < T2|T1, T2 > tmax) is not estimable, but can be conserva-
tively assumed to be 1/2 as in Begg et al., or assumed to be equal to the overall concordance
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P (T1 < T2). The latter is adopted in our method. That is,
Pˆ (T1 < T2) =
∑
t∈{t}j [Sˆj(t
−)− Sˆj(t)]Sˆi(t)
1− Sˆ1(tmax)Sˆ2(tmax)
. (11)
Similarly the second part of (6) can be estimated as
Pˆ (S1 = S2, T1 < T2) =
1
2
∑
i
Ni(Ni − 1)
N(N − 1) (12)
and the overall concordance estimator is given by
Kˆ = 2
∑∑
j>i
{
NjNi
N(N − 1)
∑
t∈{t}j [Sˆj(t
−)− Sˆj(t)]Sˆi(t)
1− Sˆ1(tmax)Sˆ2(tmax)
}
+
1
2
∑
i
Ni(Ni − 1)
N(N − 1) . (13)
The new estimator improves upon Harrells c-index, particularly in the presence of a
large amount of censoring, by including comparisons between censored individuals. It is also
much faster to implement than Begg’s method. The statistic suffers from the usual criticism
applied to concordance statistics; that is, they look only at the ranks of individuals and thus
might be insensitive to small model improvements. Using survival times, however, often
requires parametric modeling and alternative measures that are sensitive to small changes
can also be sensitive to model choice. Using ranks can also be a benefit in that K is robust
to outlying observations.
5 Analysis of Colorectal Cancer Data
We illustrated the utility of the proposed method by applying it to the staging of colorectal
cancer. The number of stages is given as k = 3 and k = 6, corresponding to numbers of main
and sub-stages in the 6th edition AJCC staging system. For the percent explained variation
and the area under the curve measures, we tried both landmark times of 5 years and 10
years, based on the median follow-up time, and the results are very similar. We hence report
here only the results from the 10-year landmark analysis.
5.1 Bootstrap Selection
The staging systems selected by maximizing the bootstrap estimates of each of the criteria
described in Section 4, given k = 3 and k = 6, respectively, are presented in Figure 3, as well
9
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as the AJCC system for comparison. The systems selected by the three criteria are similar
to each other and quite different from the AJCC system. Unlike the AJCC which separates
stage 3 horizontally at N1, the bootstrap selected systems all classify groups primarily by
the T categories (vertically). This is consistent with what we observe in Table 2, where
the estimated 10-year survivals are much lower and the hazard ratios are much greater in
categories T3 and T4.
Figure 3: Schematic showing staging systems selected by bootstrap and the AJCC 6th edition
staing system. VAR: explained variation; AUC: area under the ROC curve; K: concordance
probability.
Table 4: Selected systems and the AJCC: the estimated criteria and their standard errors.
Criteria (SE)
System VAR AUC K
k = 3
A1 0.684 (0.010) 0.705 (0.011) 0.662 (0.008)
A2 0.684 (0.010) 0.705 (0.012) 0.663 (0.007)
AJCC 0.627 (0.008) 0.643 (0.011) 0.622 (0.008)
k = 6
B1 0.688 (0.009) 0.708 (0.011) 0.667 (0.008)
B2 0.688 (0.009) 0.709 (0.011) 0.666 (0.008)
B3 0.687 (0.009) 0.708 (0.011) 0.667 (0.007)
AJCC 0.642 (0.012) 0.660 (0.013) 0.623 (0.008)
Let A1 and A2 denote the 3-stage systems selected by explained variation, and by area
under the curve and concordance probability, respectively, and let B1, B2, and B3 denote
the 6-stage systems selected by the three criteria, respectively. Table 4 shows the estimated
value of the three criteria for these selected systems and the AJCC. The bootstrap selected
10
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systems are very similar with respect to all three criteria, which is not surprising given that
the systems highly resemble each other. The prognostic power increases minimally as the
number of stages increase from 3 to 6, indicating there is not much to gain by adding more
sub-stages. In addition, of course, a 3-stage system is easier to use than a 6-stage one. The
AJCC system is substantially inferior to the selected ones in all cases, indicating there is
much room for improvement in the current system using our criteria.
Kaplan-Meier survival curves for the selected staging systems are displayed in Figure 4.
All five systems show a substantial degree of prognostic separation and a clear advantage
over the AJCC system in Figure 2. There is considerable overlap of survival curves in the
right panel because of the larger number of stages, which again raise the question whether 6
distinct stages are too many.
5.2 Confidence Intervals
The bootstrap selection provides inference procedures for not only the optimal selected, but
all candidate systems. Figure 5 shows the confidence intervals of each of the criteria for the
top-ranked systems and the AJCC. The systems are ordered by their rankings with regard to
the bootstrap estimated criteria. The top systems are in fact very close in terms of prognostic
power, especially for 6-stage systems where the top 100 systems are virtually identical due
to the fact that the systems are only slightly different from one another in their definition.
It is hence difficult to select one best system, but it allows flexibility in the decision making
process for clinical researchers, who might incorporate both statistical evidence and medical
insight into their considerations. Among the 388 3-stage systems (only the top 150 shown),
the AJCC ranks around 135 (35%), and it ranks around 12500 (60%) among the 20707 6-
stage systems (the top 125 shown). Again, the AJCC demonstrates clearly lower prognostic
power than the top systems.
5.3 Majority Vote Rule
Instead of choosing the system to maximize the bootstrap estimated criteria, the optimal
staging system can also be decided by a simple majority vote rule. For each bootstrap
replication, the candidate systems are ranked with respect to the criterion, and the systems
ranked top 10 at least 5% of the time are defined to be “good” staging systems. We show
these “good” systems in Figure 6. There is an obvious differential effect for 3-stage systems;
the top-3 ranked systems are consistent under all criteria and enjoy a majority of votes. This
11
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is not the case for 6-stage systems whose votes are very widely spread.
The x-axis represents the index of the candidate systems. Among the 3-stage systems,
candidates #38, #8, and #63 are constantly selected as the top systems, showing a clear
advantage over other candidates. Candidates #38 and #8 are in fact systems A1 and A2,
respectively, in Section 5.1. The top-ranked 6-stage systems, #8314, #7371, and #8032,
correspond to systems B1, B2, and B3, respectively. The AJCC system is included but it is
never ranked top 10.
6 Discussion and Conclusions
An accurate staging system is crucial for predicting patient outcome and guiding treatment
strategy. For decades investigators have developed and refined stage groupings using a
combination of medical knowledge and observational studies, yet there appears to be no well
established statistical method for objectively incorporating quantitative evidence into this
process. In this paper, we have proposed a systematic selection method for the development
of cancer staging systems, and illustrated the utility of this method by applying it to the
staging of colorectal cancer. The staging systems selected by the three criteria are similar to
each other while quite different from and superior to the current AJCC system, indicating
there might be room for improvement in selecting it.
It is important to remember that staging, here and in the innumerable articles in the
medical literature which discuss it, is undoubtedly confounded with treatment. The practical
implication of this is that two or more groups of patients which are placed in the same
stage may belong together either because their cancers’ prognoses are intrinsically similar
or because additional treatment to those with more advanced disease makes them so, or
some combination of the two. Begg et al. concisely summarized one way to view the issue:
“However, in thymoma, as in cancer in general, the relative impact of available treatments
on cancer survival is much smaller than the impact of anatomical stage at diagnosis, and thus
any confounding effect of the treatment is likely to be small. Furthermore, for thymoma,
there is no widespread agreement on the ideal therapy. This, allied to the fact that the
patients in our series were assembled from many different institutions for referral pathology,
resulted in a wide variation of treatments administered by stage.”
Our analysis of the colorectal cancer data has provided some insight into the prognostic
power of the TNM staging system. The selected systems (A1, A2, B1, B2, and B3) are
virtually identical in their prognostic accuracy regardless of which of the three evaluative
12
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measures is used. The selected 6-stage systems are a further division of the 3-stage systems
with no apparent improvement in separating the survivals. Thus, it might be reasonable to
favor a more parsimonious system as urged in Go¨nen and Weiser [2]. All final systems suggest
that the most essential information is contained in the contrast between the tumor invading
through the muscularis propria (T3 and T4) and otherwise (T1 and T2). This is in sharp
contrast to AJCC where the primary distinction is between node-positive (N1 and N2) and
node-negative (N0) cancers. Other near-top systems can be identified from the confidence
interval plot or the bar plot showing the majority voted systems, and a compromise can be
reach between statistical evaluation and medical judgment and common sense.
We use bootstraps to provide bias-corrected estimates of performance for the staging
systems. This addresses the internal validity which is a prerequisite for external validity yet
does not guarantee it. External validity of a prognostic system can be established by being
tested and found accurate across increasingly diverse settings. The selected systems should
be tested across multiple independent investigators, geographic sites, and follow-up periods
for accuracy and generalizability.
We define nmin as the pre-specified minimum size of a stage and, in our analysis, choose
nmin to be 5% of the sample size. It could be absolute instead of relative (e.g. nmin = 50).
Alternatives to using nmin are possible, for example, by demanding each stage’s estimated
survival or criterion have a confidence interval of given maximum width.
TNM staging is applicable to virtually any type of solid tumor hence, although we used
colorectal cancer as illustration, our methodology has general appeal. In addition other
diseases also use aggregate risk scores based on ordinal (or ordinalized) risk factors, such as
the ATP III score for high-blood cholesterol that can benefit from optimal aggregation [15].
Our methodology is applicable in principle to binary outcomes as well since, in this case, θˆi’s
in (3) can be dircetly estimated from the observed event rates in each risk category.
Cancer staging has been as much about anatomic interpetation as it is about accurate
prognosis. A staging system that is prognostically optimal is unlikely to be adopted if it
does not respect the anatomic extent of disease. Our results for colorectal cancer suggest
that prognostically optimal systems are also anatomically interpretable. The substantial
difference between the prognostic ability of the optimal systems and the AJCC categories is
concerning especially in light of the fact that optimal systems are comparable to AJCC in
terms of simplicity and interpretability.
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Figure 4: Cancer-specific survival of colorectal cancer patients by the selected staging sys-
tems. Left panel: 3-stage systems; right panel: 6-stage systems.
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Figure 5: Confidence intervals for the criteria: the top-ranked systems and the AJCC (red).
Left panel: 3-stage systems; right panel: 6-stage systems.
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Figure 6: Majority voted systems. Grey bars show the % time each system is ranked from #1
to #10, and the systems are ordered by their % time ranked #1. The x-axis represents the
index of the candidate systems. Left panel: 3-stage systems; right panel: 6-stage systems.
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